About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
Tue, 23-May-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
Fri, 28-Apr-2023
Posted by: Biocon Biologics
No Comments
Serum & Biocon Biologics Agree to Restructure Equity Investment
Tue, 25-Apr-2023
Posted by: Biocon Biologics
No Comments
Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments
Mon, 03-Apr-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
Tue, 28-Mar-2023
Posted by: Biocon Biologics
No Comments
Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
Thu, 09-Mar-2023
Posted by: Biocon Biologics
No Comments
Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
Thu, 22-Dec-2022
Posted by: Biocon Biologics
No Comments
Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
Mon, 05-Dec-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
Tue, 29-Nov-2022
Posted by: Biocon Biologics
No Comments
Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
Tue, 15-Nov-2022
Posted by: Biocon Biologics
No Comments
1
2
3
…
19